JANSA, Pavel, Samuel HELLER, Michal SVOBODA, Michal PAD'OUR, David AMBROZ, Vladimir DYTRYCH, Michal SIRANEC, Tomas KOVARNIK, Marián FELŠŐCI, Martin HUTYRA, Ales LINHART, Jaroslav LINDNER a Michael ASCHERMANN. Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. Journal of Clinical Medicine. BASEL: MDPI, 2020, roč. 9, č. 11, s. 1-15. ISSN 2077-0383. Dostupné z: https://dx.doi.org/10.3390/jcm9113608.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
Autoři JANSA, Pavel (203 Česká republika, garant), Samuel HELLER (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Michal PAD'OUR (203 Česká republika), David AMBROZ (203 Česká republika), Vladimir DYTRYCH (203 Česká republika), Michal SIRANEC (203 Česká republika), Tomas KOVARNIK (203 Česká republika), Marián FELŠŐCI (703 Slovensko, domácí), Martin HUTYRA, Ales LINHART (203 Česká republika), Jaroslav LINDNER a Michael ASCHERMANN (203 Česká republika).
Vydání Journal of Clinical Medicine, BASEL, MDPI, 2020, 2077-0383.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30218 General and internal medicine
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.241
Kód RIV RIV/00216224:14110/20:00117462
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/jcm9113608
UT WoS 000593224900001
Klíčová slova anglicky chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; efficacy; safety; quality of life; risk profile; survival
Štítky 14110211, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 21. 12. 2020 08:43.
Anotace
Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
VytisknoutZobrazeno: 24. 7. 2024 00:21